AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PACB · NASDAQ · Medical - Devices

PacBio

Builds HiFi sequencing platforms centered on Revio, Vega, and consumables.

$1.42

After-hours close+0.02 (+1.52%)

At close$1.40(−10.00%)

Something off on this page? Send us feedback.

Profile

Pacific Biosciences of California, Inc.PACBHealth Care

Sells long-read sequencing instruments, consumables, software, and services for genomic analysis. Consumables are the largest revenue category, and the business is refocused on HiFi long-read adoption after selling selected short-read assets.

Sells Revio and Vega sequencing systems, SMRT Cells, chemistry, sample-prep kits, software, and services built around SMRT and HiFi long-read sequencing. Customers include research institutions, service labs, public health groups, pharmaceutical companies, and agriculture users.

Revenue is reported as a single genetic-analysis platform segment across instruments, consumables, and service or other offerings. Sales span the Americas, EMEA, and Asia-Pacific, with the United States forming most of the Americas line.

Execution depends on expanding the installed base, repeat consumables use, and clinical-research adoption of HiFi sequencing. Products are generally research-use-only unless regulatory status changes, and many customers buy through purchase orders rather than long-term volume commitments.

Company facts

CEOChristian O. Henry

ListedOct 27, 2010

ExchangeNASDAQ

HeadquartersMenlo Park, CA

CountryUnited States

Employees485

CIK0001299130

ISINUS69404D1081

Key statistics

Market cap$434.8M

EPS (ttm)−$0.4300

P/E (ttm)−3.26

ROE-4,961.7%

P/B−13.09

P/S2.73

Dividend yield—

Beta2.49vs XLV 0.93

Year to date −24.2% · Average volume (30d) 7.5M

Analysts

Price target, next 12 months$1.00−28.6%Median of 18 analysts · vs the Aug 28 close

ConsensusBuy9 of 18 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $1.40

High$1.00−28.6%

Median$1.00−28.6%

Low$1.00−28.6%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Apr 14, 2026	Barclays	Reiterate		Underweight	$1.50	$1
Mar 6, 2026	Barclays	Downgrade	Equal Weight	Underweight
Nov 11, 2024	UBS	Downgrade	Buy	Neutral

Earnings

EPS

Estimate−$0.13

ReportedDue Nov 3, 2026

Revenue

Estimate$43.8M

ReportedDue Nov 3, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 3, 2026Q2 FY26	−$0.13	−$0.14	−9.4%	$42.9M	$39.0M	−9.1%	+1.41%
May 7, 2026Q1 FY26	−$0.17	−$0.12	+29.4%	$39.9M	$37.2M	−6.9%	−14.55%
Feb 12, 2026Q4 FY25	−$0.19	−$0.12	+36.8%	$43.0M	$44.6M	+3.7%	−7.07%
Nov 5, 2025Q3 FY25	−$0.16	−$0.12	+25.0%	$44.6M	$38.4M	−13.8%	−7.29%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$37.2M	$39.8M	$38.4M	$44.6M	$37.2M	$39.0M
Gross profit	−$1.4M	$14.7M	$15.1M	$16.7M	$12.8M	$12.6M
Operating income	−$428.9M	−$44.9M	−$38.8M	−$41.2M	−$37.9M	−$44.6M
Net income	−$426.1M	−$41.9M	−$38.0M	−$40.4M	−$8.3M	−$44.7M
Diluted EPS	−$1.44	−$0.14	−$0.13	−$0.13	−$0.03	−$0.14
Gross margin	-3.7%	36.9%	39.2%	37.5%	34.5%	32.4%
Operating margin	-1,154.5%	-112.8%	-101.0%	-92.3%	-102.0%	-114.4%

Fiscal years (4-quarter sums)FY21 $130.5M · FY22 $128.3M · FY23 $200.5M · FY24 $154.0M · FY25 $160.0M

Revenue by product · Q2 FY26

Product$33.0M · 46%

Consumable$20.1M · 28%

Instrument$12.8M · 18%

Service And Other$6.1M · 8%

Revenue by geography · Q2 FY26

Americas$17.6M · 45%

EMEA$14.4M · 37%

Asia Pacific$7.0M · 18%

Balance sheet, Jun 30, 2026Cash & short-term investments $236.9M · Total debt $706.1M · Total assets $751.9M · Shareholders' equity −$33.2M

Dividends

No dividends on record.

Ownership

Institutions 60.59%188.19M sharesInsiders 2.56%7.95M sharesOther 36.85%114.46M shares

Shares outstanding 310.60M · Float 303.83M · 97.8% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Ark Investment Management LLC	36.27M	11.68%	13F	May 12, 2026
BlackRock, Inc.	25.27M	8.13%	13F	May 13, 2026
SoftBank Group Corp.	20.45M	6.58%	13F	May 15, 2026
SB Northstar LP	20.45M	7.50%	13G	Nov 26, 2024
Vanguard Capital Management LLC	12.78M	4.11%	13F	May 15, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 17, 2026	Mark van Oene	officer: See Remarks	−26,911	$1.13
Apr 1, 2026	James R. II Gibson	officer: See Remarks	−88,185	$1.37
Mar 3, 2026	Michele Farmer	officer: See Remarks	−2,979	$1.51
Mar 3, 2026	Mark van Oene	officer: See Remarks	−6,504	$1.51
Mar 3, 2026	Christian O. Henry	officer: See Remarks	−12,497	$1.51